FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283691497> ?p ?o ?g. }

• W4283691497 endingPage "1141" @default.
• W4283691497 startingPage "1141.1" @default.
• W4283691497 abstract "Background Tocilizumab (TCZ) is a disease-modifying antirheumatic biologic drug, which targets the IL-6 signalling pathway and is effective in ameliorating disease activity in rheumatoid arthritis (RA). However, approximately 50% of patients do not respond adequately to TCZ and some patients report adverse events. Considering there is growing evidence that DNA methylation is implicated in RA susceptibility and response to some biologics (1, 2), we investigated DNA methylation as a candidate biomarker for response to TCZ in RA. Objectives To identify differential DNA methylation signatures in whole blood associated with TCZ response in patients with RA. Methods Epigenome-wide DNA methylation patterns were measured using the Infinium EPIC 850k BeadChip (Illumina) in whole blood-derived DNA samples from patients with RA. DNA was extracted from blood samples taken pre-treatment and following 3 months on therapy, and response was determined at 6 months using the Clinical Disease Activity Index (CDAI). Patients who had good response (n=10) or poor response (n=10) to TCZ by 6 months were selected. Samples from secondary poor responders (n=10) (patients who had an improvement of CDAI and were in remission at 3 months, followed by a worsening of CDAI at 6 months) were also analysed. Differentially methylated positions (DMPs) were identified using linear regression, adjusting for gender, age, cell composition, smoking status, and glucocorticoid use. Results In the pre-treatment samples, 20 DMPs were significantly associated with response status at 6 months (unadjusted p-value <10 -6 ), whilst in the 3 month samples, 21 DMPs were associated with response. One DMP, cg03121467, was significantly less methylated in good responders compared to poor responders in the pre-treatment samples. This DMP is close to EPB41L4A and may play a role in β–catenin signalling. Interestingly, cg10136146 was significantly less methylated in secondary poor responders compared to both good and poor responders in the 3 month samples. This DMP maps close to CD81 , which plays a role in mediating the development and activation of B and T lymphocytes. Conclusion These preliminary results provide evidence that DNA methylation patterns may predict response to TCZ. Further regional and pathway analyses is in progress and validation of these findings in other larger data sets is required. References [1]Liu,Y., Aryee,M.J., Padyukov,L., Fallin,M.D., Hesselberg,E., Runarsson,A., Reinius,L., Acevedo,N., Taub,M., Ronninger,M., et al. (2013) Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. , 31 , 142–147. [2]Plant,D., Webster,A., Nair,N., Oliver,J., Smith,S.L., Eyre,S., Hyrich,K.L., Wilson,A.G., Morgan,A.W., Isaacs,J.D., et al. (2016) Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. (Hoboken, N.J. ), 68 , 1353–60. Disclosure of Interests Nisha Nair: None declared, Darren Plant: None declared, John Isaacs Speakers bureau: Abbvie, Gilead, Roche, UCB, Grant/research support from: GSK, Janssen, Pfizer, Ann Morgan Speakers bureau: Roche/Chugai, Consultant of: GSK, Roche, Chugai, AstraZeneca, Regeneron, Sanofi, Vifor, Grant/research support from: Roche, Kiniksa Pharmaceuticals, Kimme Hyrich Consultant of: AbbVie, Grant/research support from: Pfizer, BMS, Anne Barton Grant/research support from: I have received grant funding from Pfizer, Galapagos, Scipher Medicine and Bristol Myers Squibb., Anthony G Wilson: None declared" @default.
• W4283691497 created "2022-06-30" @default.
• W4283691497 creator A5000205562 @default.
• W4283691497 creator A5002720368 @default.
• W4283691497 creator A5006159462 @default.
• W4283691497 creator A5025822582 @default.
• W4283691497 creator A5026061253 @default.
• W4283691497 creator A5052690908 @default.
• W4283691497 creator A5077844293 @default.
• W4283691497 date "2022-05-23" @default.
• W4283691497 modified "2023-09-27" @default.
• W4283691497 title "AB0011 DNA METHYLATION AS A BIOMARKER OF TOCILIZUMAB RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS" @default.
• W4283691497 doi "https://doi.org/10.1136/annrheumdis-2022-eular.3102" @default.
• W4283691497 hasPublicationYear "2022" @default.
• W4283691497 type Work @default.
• W4283691497 citedByCount "0" @default.
• W4283691497 crossrefType "journal-article" @default.
• W4283691497 hasAuthorship W4283691497A5000205562 @default.
• W4283691497 hasAuthorship W4283691497A5002720368 @default.
• W4283691497 hasAuthorship W4283691497A5006159462 @default.
• W4283691497 hasAuthorship W4283691497A5025822582 @default.
• W4283691497 hasAuthorship W4283691497A5026061253 @default.
• W4283691497 hasAuthorship W4283691497A5052690908 @default.
• W4283691497 hasAuthorship W4283691497A5077844293 @default.
• W4283691497 hasBestOaLocation W42836914971 @default.
• W4283691497 hasConcept C104317684 @default.
• W4283691497 hasConcept C126322002 @default.
• W4283691497 hasConcept C143998085 @default.
• W4283691497 hasConcept C150194340 @default.
• W4283691497 hasConcept C185592680 @default.
• W4283691497 hasConcept C190727270 @default.
• W4283691497 hasConcept C198451711 @default.
• W4283691497 hasConcept C203014093 @default.
• W4283691497 hasConcept C2777178219 @default.
• W4283691497 hasConcept C2777575956 @default.
• W4283691497 hasConcept C2781197716 @default.
• W4283691497 hasConcept C33288867 @default.
• W4283691497 hasConcept C54355233 @default.
• W4283691497 hasConcept C552990157 @default.
• W4283691497 hasConcept C55493867 @default.
• W4283691497 hasConcept C71924100 @default.
• W4283691497 hasConcept C86803240 @default.
• W4283691497 hasConcept C90924648 @default.
• W4283691497 hasConceptScore W4283691497C104317684 @default.
• W4283691497 hasConceptScore W4283691497C126322002 @default.
• W4283691497 hasConceptScore W4283691497C143998085 @default.
• W4283691497 hasConceptScore W4283691497C150194340 @default.
• W4283691497 hasConceptScore W4283691497C185592680 @default.
• W4283691497 hasConceptScore W4283691497C190727270 @default.
• W4283691497 hasConceptScore W4283691497C198451711 @default.
• W4283691497 hasConceptScore W4283691497C203014093 @default.
• W4283691497 hasConceptScore W4283691497C2777178219 @default.
• W4283691497 hasConceptScore W4283691497C2777575956 @default.
• W4283691497 hasConceptScore W4283691497C2781197716 @default.
• W4283691497 hasConceptScore W4283691497C33288867 @default.
• W4283691497 hasConceptScore W4283691497C54355233 @default.
• W4283691497 hasConceptScore W4283691497C552990157 @default.
• W4283691497 hasConceptScore W4283691497C55493867 @default.
• W4283691497 hasConceptScore W4283691497C71924100 @default.
• W4283691497 hasConceptScore W4283691497C86803240 @default.
• W4283691497 hasConceptScore W4283691497C90924648 @default.
• W4283691497 hasIssue "Suppl 1" @default.
• W4283691497 hasLocation W42836914971 @default.
• W4283691497 hasOpenAccess W4283691497 @default.
• W4283691497 hasPrimaryLocation W42836914971 @default.
• W4283691497 hasRelatedWork W1984273828 @default.
• W4283691497 hasRelatedWork W1987294331 @default.
• W4283691497 hasRelatedWork W2035343580 @default.
• W4283691497 hasRelatedWork W2046399730 @default.
• W4283691497 hasRelatedWork W2094304284 @default.
• W4283691497 hasRelatedWork W2123582592 @default.
• W4283691497 hasRelatedWork W2558297493 @default.
• W4283691497 hasRelatedWork W2736593664 @default.
• W4283691497 hasRelatedWork W2996380604 @default.
• W4283691497 hasRelatedWork W4239841759 @default.
• W4283691497 hasVolume "81" @default.
• W4283691497 isParatext "false" @default.
• W4283691497 isRetracted "false" @default.
• W4283691497 workType "article" @default.